Wellorithm Review: It Advertises No Membership Fees — Its Own Terms Bill Them Every 28 Days

What Is Wellorithm?

Wellorithm launched its affiliate programme on 3 April 2026, making it roughly four months old at the time of this review. It sells compounded semaglutide and tirzepatide in both injection and orally disintegrating tablet form, brand-name Wegovy, Ozempic, Zepbound and Mounjaro, and NAD+ and sermorelin. It advertises service in all 50 states with licensed US doctors, free shipping, HSA/FSA acceptance and a 24/7 support line on +1 (877) 402-6778.

Its compounding disclosure is correct and prominently placed on the homepage: 'Compounded medications have not been reviewed or approved by the FDA for safety, effectiveness, or quality. Your healthcare provider will collaborate with you to decide which, if any, medication is appropriate for your individual healthcare needs.' That is the right statement and we credit it.

Carrying brand-name products alongside compounded ones is also genuinely useful — it gives patients with insurance or a strong preference for FDA-approved medication an option in the same place.

Everything else about this company is difficult to reconcile. Its own terms and conditions describe it as 'a Miami-based company' while listing a contact address of '785 15h Street, Office 478 Berlin, De 81566' — a German address, with a typo in the street number, and a postcode that does not correspond to Berlin. Disputes are governed by New York law with arbitration through JAMS in New York. No legal entity name — no LLC, no Inc., nothing — appears anywhere on the site or in the terms.

For a business prescribing medication to Americans in all 50 states, not being able to establish what company it is or where it operates from is not a technicality.

Medications & Pricing

The compounded prices are competitive and the brand-name range is a genuine convenience. What you cannot establish from the page is what you will actually be charged, because the campaign page states 'No membership or hidden fees! Everything you need is included' while the terms and conditions state 'Membership fees are billed every 28 days, and payments are non-refundable once processed.' Note also what a 28-day cycle means: thirteen billing cycles a year rather than twelve. On a $147 plan that is an extra $147 annually compared with monthly billing, and it is the kind of detail that only becomes visible on a bank statement. Establish your total annual cost, in writing, before you enrol.

Compounded vs Brand-Name — What's Approved Here

Wellorithm gets the core disclosure right, and it deserves saying: its homepage states that 'Compounded medications have not been reviewed or approved by the FDA for safety, effectiveness, or quality', and adds that your provider will decide 'which, if any, medication is appropriate'. That is accurate and appropriately placed.

Understand what it means in practice. Compounded semaglutide and tirzepatide contain the same active molecules as Wegovy and Zepbound, but the finished products have not been through FDA review for safety, efficacy or manufacturing quality. The published trial results — the ones behind every weight-loss figure you have read — come from the branded products. Sterility and potency depend entirely on the compounding pharmacy, and Wellorithm does not name its pharmacy.

The orally disintegrating tablets warrant particular scepticism. Semaglutide is a peptide destroyed by digestion, which is why the only FDA-approved oral version, Rybelsus, uses a specific absorption enhancer and requires precise dosing conditions. Compounded ODT semaglutide is not that product and its absorption is not documented. If you are choosing a tablet over an injection to avoid needles, ask the prescriber directly what evidence exists that the dose reaches your bloodstream.

NAD+ and sermorelin at $150 a month each carry the same unapproved status with thinner evidence again. On NAD+ specifically, the FDA has warned that compounders have used food-grade NAD+ to make injectable products, cautioning that food-grade ingredients 'are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins'.

The brand-name products are the exception and the reason to consider this service at all: Wegovy at $899 and Zepbound at $1,199 are FDA-approved, manufactured by Novo Nordisk and Eli Lilly, and are the products the trials actually studied. Note the correct distinction Wellorithm partly makes — Ozempic and Mounjaro are approved for type 2 diabetes rather than weight management, and prescribing them for weight is off-label.

The Consultation Process

Eligibility

• •Adults in the United States, following an online assessment and clinician review. Wellorithm advertises service in all 50 states.
• •GLP-1 medicines are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and must not be used in pregnancy or while trying to conceive.
• •Clinician judgement is required for anyone with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease including gastroparesis, or diabetic retinopathy.
• •Common side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation and reflux — usually worst after a dose increase. Less common but serious risks include pancreatitis, gallbladder disease and dehydration-related kidney injury.
• •Rapid weight loss costs lean muscle as well as fat. Attend to protein intake and resistance training, and be sceptical of the site's testimonial claiming '17% increased muscle' during weight loss — that is not a typical or expected outcome.
• •Sermorelin should not be used by anyone with active cancer, and cancer survivors should decide alongside an oncologist.
• •If you stop a GLP-1, appetite generally returns and weight regain is common. Treat this as long-term treatment when assessing the cost, particularly on a 28-day billing cycle.

Clinicians, Labs & Pharmacy

Shipping & Support Services

Free shipping is advertised throughout, described as fast. No delivery timeframe is published.

• •Correct and prominent compounded-drug disclaimer on the homepage
• •Brand-name Wegovy, Ozempic, Zepbound and Mounjaro offered alongside compounded options
• •Competitive compounded pricing — semaglutide from $147, tirzepatide from $249
• •$100 off the first month advertised on compounded products
• •A defined weight-loss guarantee with stated criteria, rather than a vague promise
• •A 30-day window to opt out of the arbitration clause
• •HSA and FSA accepted
• •Free shipping
• •24/7 phone support line published
• •Needle-free ODT options available

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who Wellorithm May Be Best For

• •We would not recommend enrolling until the company can be identified and the membership-fee contradiction resolved
• •If you want brand-name medication, established providers offer it with a verifiable corporate identity
• •If you want the lowest compounded price, providers with inspectable records charge less
• •Anyone who does proceed should get the fee structure, billing frequency and refund terms in writing first

Limitations

• •Start with the contradiction, because it concerns your money and it is unambiguous. The campaign page says: 'No membership or hidden fees! Everything you need is included.' The terms and conditions say: 'Membership fees are billed every 28 days, and payments are non-refundable once processed.' Those are irreconcilable, and the terms are the document that binds you. The 28-day cycle compounds it: thirteen billing periods a year rather than twelve means an extra charge annually that nobody budgets for, and combined with 'non-refundable once processed' it means a mistimed cancellation costs you a full cycle.
• •Then the question of who this company actually is. Its own terms describe it as 'a Miami-based company'. Its footer and its terms both give an address of '785 15h Street, Office 478 Berlin, De 81566' — a German address, with a typo in the street number, and a postcode that is not a Berlin postcode. Disputes are governed by New York law with arbitration in New York. No legal entity name appears anywhere: no LLC, no corporation, nothing you could look up in any registry. For a business prescribing medication to patients in all fifty US states, that is not a formatting oversight — it is the absence of the single fact you would need in order to hold anyone accountable.
• •The social proof does not survive arithmetic either. The campaign page claims to have more than 100,000 patients. The affiliate programme for this company launched on 3 April 2026 — four months before this review. Even allowing that a business can exist before it recruits affiliates, a hundred thousand patients is a very large claim from an operation with no BBB profile, no Trustpilot presence and no independent footprint we could find anywhere. '100% Customer Satisfaction' is an absolute that no business achieves.
• •The outcome claims are the part most likely to mislead someone medically rather than financially. A calculator returns a 46 lb projection from a 200 lb starting weight — 23% of body weight, above the roughly 15% average in semaglutide's pivotal trial. Testimonials cite '17% increased muscle', '55% sleep improvement' and '65% less cravings' — precise-sounding figures with no source, and in the case of muscle gain during rapid weight loss, contrary to what generally happens.
• •It is worth being fair about what is genuinely good here, because there are two things. The compounded-drug disclaimer is correct and prominently placed, which several better-established competitors fail at. And the weight-loss guarantee, unlike most in this market, has defined criteria: 10% of baseline weight, 16 weeks of adherence, up to four months of fees refunded, verified by doctor's attestation or a video of a calibrated scale. That is a real commitment with real conditions rather than a slogan. It would carry considerably more weight if you could establish which company was making it.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

Wellorithm does two things right. Its compounding disclosure is correct and sits prominently on the homepage — compounded medications 'have not been reviewed or approved by the FDA for safety, effectiveness, or quality' — which several longer-established competitors never manage. And its weight-loss guarantee has genuinely defined criteria: 10% of baseline weight, 16 weeks of adherence, up to four months of fees refunded, verified properly. That is a real commitment rather than a slogan.

Everything else needs resolving before anyone should pay it money. The campaign page promises 'No membership or hidden fees'. The terms and conditions bill 'membership fees every 28 days' and make payments 'non-refundable once processed'. Twenty-eight-day billing means thirteen charges a year rather than twelve, and a mistimed cancellation costs a full cycle. Those two statements about fees cannot both be true, and the binding one is the less favourable.

Then there is the question of who is making the promise. The terms describe a 'Miami-based company' and give a Berlin address with a typo and a mismatched postcode, while specifying New York law and New York arbitration. No legal entity name appears anywhere — nothing you could look up in any registry, in any of those three jurisdictions. For a business prescribing medication in all fifty states, that is the single most important missing fact.

The claims compound the impression. More than 100,000 patients, from a company four months old with no BBB profile, no reviews and no public footprint. '100% Customer Satisfaction.' A calculator projecting 23% weight loss. A testimonial reporting a 17% muscle gain during a period of rapid weight loss.

We rate Wellorithm 2.2 out of 5 — competitive prices and one correct disclosure, attached to a company whose own documents cannot agree on what it charges or which continent it is on.

We would not enrol until the fee structure and the corporate identity are established in writing. If you want compounded semaglutide, providers with inspectable records charge less than $147. If you want brand-name medication, check whether your insurance covers it before paying $899 to $1,399 in cash.

This review is informational only and is not medical advice. Compounded semaglutide, tirzepatide, NAD+ and sermorelin are not FDA-approved. Speak to a licensed clinician about whether treatment is appropriate for you before starting, changing or stopping any medication.